# AnaptysBio AnaptysBio is an Asset Manager based in San Diego, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** San Diego, United States - **Region:** North America - **Address:** San Diego, CA, United States - **Founded:** 2005 - **Assets under management:** Undisclosed - **Website:** anaptysbio.com ## Regulatory record - **Reports private funds:** No ## About AnaptysBio was founded in 2005 and is headquartered in San Diego, California. The company's foundation rests on its somatic hypermutation (SHM) platform, which replicates the body's natural antibody generation process to produce novel therapeutic candidates. This technology has yielded multiple partnership deals, most notably with GlaxoSmithKline and Bristol Myers Squibb, validating the engine's ability to generate valuable clinical assets. AnaptysBio deploys its platform across two primary strategies: advancing wholly-owned internal programs and generating partnered pipeline assets. The internal pipeline is focused on immunology, led by imsidolimab, an anti-IL-36 receptor antibody in Phase 3 trials for generalized pustular psoriasis, and rosnilimab, a PD-1 agonist in Phase 2 development for rheumatoid arthritis and ulcerative colitis. Partnered programs include GSK's cobolimab, an anti-TIM-3 antibody, and earlier-stage assets licensed to Bristol Myers Squibb. The company's therapeutic focus is concentrated on the United States and European clinical trial sites. As of mid-2026, Daniel Faga leads the company as President and CEO, having succeeded Hamza Suria in that role. The management team includes Paul Lizzul as Chief Medical Officer. In March 2024, AnaptysBio reported positive top-line Phase 3 data for imsidolimab in generalized pustular psoriasis, a key de-risking event for the company's most advanced internal asset. The firm operates from its San Diego headquarters with a historically lean operational footprint. AnaptysBio's structural differentiation lies in its dual identity as both a platform company and a pipeline developer. Unlike pure-play biotech firms that in-license assets, AnaptysBio generates its own therapeutic candidates from its SHM-72 antibody engine, then advances a select few through clinical development while monetizing others through partnerships. This hybrid model creates an internal funding mechanism via milestone payments and royalties that partially offsets the cash burn from its wholly-owned clinical programs. ## Sectors - Digital Health - Healthcare Services ## People - Daniel Faga — President & Chief Executive Officer - Paul F. Lizzul — Chief Medical Officer ## Questions ### Who runs investment decisions at AnaptysBio? AnaptysBio is a clinical-stage biotechnology company, not an investment firm. Capital allocation toward pipeline programs is governed by the executive leadership team, led by President and CEO Daniel Faga, in conjunction with the Board of Directors. Strategic partnership decisions, such as the licensing deals with GSK and Bristol Myers Squibb, are executed by corporate development leadership under board oversight. ### How does AnaptysBio source its drug candidates? AnaptysBio generates therapeutic antibody candidates internally using its proprietary somatic hypermutation (SHM-72) platform. This engine mimics the human immune system's natural antibody maturation process in vitro, producing fully human antibodies without relying on mouse immunization or phage display. The platform's output has been validated by partnerships with GlaxoSmithKline and Bristol Myers Squibb. ### Which therapeutic areas does AnaptysBio target for its internal pipeline? AnaptysBio's wholly-owned pipeline concentrates on immunology, specifically inflammatory and autoimmune diseases. Lead programs include imsidolimab, an anti-IL-36 receptor antibody for generalized pustular psoriasis, and rosnilimab, a PD-1 agonist being investigated in rheumatoid arthritis and ulcerative colitis. The company has publicly stated it does not currently pursue oncology indications internally. ### What is AnaptysBio's relationship with GlaxoSmithKline and Bristol Myers Squibb? AnaptysBio has out-licensed antibodies generated from its SHM-72 platform to both pharmaceutical companies. GSK advanced cobolimab, an anti-TIM-3 antibody, through clinical trials, while Bristol Myers Squibb licensed earlier-stage programs. These partnerships provide AnaptysBio with milestone payments and potential royalties, creating a capital-efficient funding model alongside its internal pipeline development. ### Is AnaptysBio structured as a platform company or a traditional biotech? AnaptysBio operates a hybrid structure, functioning as both a technology platform and a pipeline developer. The SHM-72 antibody generation engine supplies candidates for its own clinical programs while also producing assets for partnered development with large pharmaceutical companies. This dual-track model distinguishes it from biotech firms that exclusively in-license or acquire clinical-stage assets. ## Related profiles - [Abaxx Technologies Inc.](https://altss.com/profile/abaxx-technologies-inc) - [Pathward Financial](https://altss.com/profile/pathward-financial-inc) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/anaptysbio-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology